Verition Fund Management LLC Sells 10,504 Shares of Hologic, Inc. (NASDAQ:HOLX)

Verition Fund Management LLC decreased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 52.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,345 shares of the medical equipment provider's stock after selling 10,504 shares during the quarter. Verition Fund Management LLC's holdings in Hologic were worth $761,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after buying an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock worth $208,051,000 after acquiring an additional 18,774 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock worth $200,952,000 after purchasing an additional 195,285 shares in the last quarter. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Hologic by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock valued at $172,780,000 after purchasing an additional 124,739 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Raymond James raised their price target on Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. Jefferies Financial Group assumed coverage on Hologic in a report on Tuesday. They set a "hold" rating and a $85.00 price objective for the company. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and reduced their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 1st. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.50.

Hologic Trading Up 1.4 %

Shares of HOLX traded up $1.04 during trading hours on Tuesday, reaching $76.83. The stock had a trading volume of 3,995,593 shares, compared to its average volume of 1,611,400. The firm has a 50-day moving average of $79.62 and a 200 day moving average of $78.60. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $17.44 billion, a P/E ratio of 23.07, a P/E/G ratio of 2.37 and a beta of 0.96. Hologic, Inc. has a 52 week low of $68.15 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the firm posted $0.89 earnings per share. Hologic's revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.